Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Aspirin and Hemocompatibility Events With a Left Ventricular Assist Device in Advanced Heart Failure: The ARIES-HM3 Randomized Clinical Trial

MR. Mehra, I. Netuka, N. Uriel, JN. Katz, FD. Pagani, UP. Jorde, F. Gustafsson, JM. Connors, P. Ivak, J. Cowger, J. Ransom, A. Bansal, K. Takeda, R. Agarwal, M. Byku, MM. Givertz, A. Bitar, S. Hall, D. Zimpfer, JD. Vega, MK. Kanwar, O. Saeed, DJ....

. 2023 ; 330 (22) : 2171-2181. [pub] 2023Dec12

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem, komentáře

Perzistentní odkaz   https://www.medvik.cz/link/bmc24000255
E-zdroje Online Plný text

NLK Open Access Digital Library od 1998-01-01 do Před 6 měsíci
Medline Complete (EBSCOhost) od 1998-01-07 do Před 1 měsícem

Odkazy

PubMed 37950897
DOI 10.1001/jama.2023.23204
Knihovny.cz E-zdroje

IMPORTANCE: Left ventricular assist devices (LVADs) enhance quality and duration of life in advanced heart failure. The burden of nonsurgical bleeding events is a leading morbidity. Aspirin as an antiplatelet agent is mandated along with vitamin K antagonists (VKAs) with continuous-flow LVADs without conclusive evidence of efficacy and safety. OBJECTIVE: To determine whether excluding aspirin as part of the antithrombotic regimen with a fully magnetically levitated LVAD is safe and decreases bleeding. DESIGN, SETTING, AND PARTICIPANTS: This international, randomized, double-blind, placebo-controlled study of aspirin (100 mg/d) vs placebo with VKA therapy in patients with advanced heart failure with an LVAD was conducted across 51 centers with expertise in treating patients with advanced heart failure across 9 countries. The randomized population included 628 patients with advanced heart failure implanted with a fully magnetically levitated LVAD (314 in the placebo group and 314 in the aspirin group), of whom 296 patients in the placebo group and 293 in the aspirin group were in the primary analysis population, which informed the primary end point analysis. The study enrolled patients from July 2020 to September 2022; median follow-up was 14 months. INTERVENTION: Patients were randomized in a 1:1 ratio to receive aspirin (100 mg/d) or placebo in addition to an antithrombotic regimen. MAIN OUTCOMES AND MEASURES: The composite primary end point, assessed for noninferiority (-10% margin) of placebo, was survival free of a major nonsurgical (>14 days after implant) hemocompatibility-related adverse events (including stroke, pump thrombosis, major bleeding, or arterial peripheral thromboembolism) at 12 months. The principal secondary end point was nonsurgical bleeding events. RESULTS: Of the 589 analyzed patients, 77% were men; one-third were Black and 61% were White. More patients were alive and free of hemocompatibility events at 12 months in the placebo group (74%) vs those taking aspirin (68%). Noninferiority of placebo was demonstrated (absolute between-group difference, 6.0% improvement in event-free survival with placebo [lower 1-sided 97.5% CI, -1.6%]; P < .001). Aspirin avoidance was associated with reduced nonsurgical bleeding events (relative risk, 0.66 [95% confidence limit, 0.51-0.85]; P = .002) with no increase in stroke or other thromboembolic events, a finding consistent among diverse subgroups of patient characteristics. CONCLUSIONS AND RELEVANCE: In patients with advanced heart failure treated with a fully magnetically levitated LVAD, avoidance of aspirin as part of an antithrombotic regimen, which includes VKA, is not inferior to a regimen containing aspirin, does not increase thromboembolism risk, and is associated with a reduction in bleeding events. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04069156.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24000255
003      
CZ-PrNML
005      
20240213093033.0
007      
ta
008      
240109s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1001/jama.2023.23204 $2 doi
035    __
$a (PubMed)37950897
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Mehra, Mandeep R $u Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts
245    10
$a Aspirin and Hemocompatibility Events With a Left Ventricular Assist Device in Advanced Heart Failure: The ARIES-HM3 Randomized Clinical Trial / $c MR. Mehra, I. Netuka, N. Uriel, JN. Katz, FD. Pagani, UP. Jorde, F. Gustafsson, JM. Connors, P. Ivak, J. Cowger, J. Ransom, A. Bansal, K. Takeda, R. Agarwal, M. Byku, MM. Givertz, A. Bitar, S. Hall, D. Zimpfer, JD. Vega, MK. Kanwar, O. Saeed, DJ. Goldstein, R. Cogswell, FH. Sheikh, M. Danter, Y. Pya, A. Phancao, J. Henderson, DL. Crandall, K. Sundareswaran, E. Soltesz, JD. Estep, ARIES-HM3 Investigators
520    9_
$a IMPORTANCE: Left ventricular assist devices (LVADs) enhance quality and duration of life in advanced heart failure. The burden of nonsurgical bleeding events is a leading morbidity. Aspirin as an antiplatelet agent is mandated along with vitamin K antagonists (VKAs) with continuous-flow LVADs without conclusive evidence of efficacy and safety. OBJECTIVE: To determine whether excluding aspirin as part of the antithrombotic regimen with a fully magnetically levitated LVAD is safe and decreases bleeding. DESIGN, SETTING, AND PARTICIPANTS: This international, randomized, double-blind, placebo-controlled study of aspirin (100 mg/d) vs placebo with VKA therapy in patients with advanced heart failure with an LVAD was conducted across 51 centers with expertise in treating patients with advanced heart failure across 9 countries. The randomized population included 628 patients with advanced heart failure implanted with a fully magnetically levitated LVAD (314 in the placebo group and 314 in the aspirin group), of whom 296 patients in the placebo group and 293 in the aspirin group were in the primary analysis population, which informed the primary end point analysis. The study enrolled patients from July 2020 to September 2022; median follow-up was 14 months. INTERVENTION: Patients were randomized in a 1:1 ratio to receive aspirin (100 mg/d) or placebo in addition to an antithrombotic regimen. MAIN OUTCOMES AND MEASURES: The composite primary end point, assessed for noninferiority (-10% margin) of placebo, was survival free of a major nonsurgical (>14 days after implant) hemocompatibility-related adverse events (including stroke, pump thrombosis, major bleeding, or arterial peripheral thromboembolism) at 12 months. The principal secondary end point was nonsurgical bleeding events. RESULTS: Of the 589 analyzed patients, 77% were men; one-third were Black and 61% were White. More patients were alive and free of hemocompatibility events at 12 months in the placebo group (74%) vs those taking aspirin (68%). Noninferiority of placebo was demonstrated (absolute between-group difference, 6.0% improvement in event-free survival with placebo [lower 1-sided 97.5% CI, -1.6%]; P < .001). Aspirin avoidance was associated with reduced nonsurgical bleeding events (relative risk, 0.66 [95% confidence limit, 0.51-0.85]; P = .002) with no increase in stroke or other thromboembolic events, a finding consistent among diverse subgroups of patient characteristics. CONCLUSIONS AND RELEVANCE: In patients with advanced heart failure treated with a fully magnetically levitated LVAD, avoidance of aspirin as part of an antithrombotic regimen, which includes VKA, is not inferior to a regimen containing aspirin, does not increase thromboembolism risk, and is associated with a reduction in bleeding events. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04069156.
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé $7 D006801
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a Aspirin $x škodlivé účinky $7 D001241
650    12
$a podpůrné srdeční systémy $x škodlivé účinky $7 D006353
650    _2
$a fibrinolytika $x škodlivé účinky $7 D005343
650    _2
$a dvojitá slepá metoda $7 D004311
650    12
$a srdeční selhání $x patofyziologie $7 D006333
650    12
$a cévní mozková příhoda $x etiologie $x prevence a kontrola $x farmakoterapie $7 D020521
650    _2
$a inhibitory agregace trombocytů $x škodlivé účinky $7 D010975
650    _2
$a krvácení $x etiologie $7 D006470
650    12
$a tromboembolie $x etiologie $x prevence a kontrola $7 D013923
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a komentáře $7 D016420
700    1_
$a Netuka, Ivan $u Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Uriel, Nir $u Columbia University College of Physicians and Surgeons and New York Presbyterian Hospital, New York
700    1_
$a Katz, Jason N $u Duke University Medical Center, Durham, North Carolina
700    1_
$a Pagani, Francis D $u University of Michigan, Ann Arbor
700    1_
$a Jorde, Ulrich P $u Montefiore Einstein Center for Heart and Vascular Care, New York, New York
700    1_
$a Gustafsson, Finn $u Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
700    1_
$a Connors, Jean M $u Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts
700    1_
$a Ivak, Peter $u Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Cowger, Jennifer $u Henry Ford Hospital, Detroit, Michigan
700    1_
$a Ransom, John $u Baptist Health Medical Center, Little Rock, Arkansas
700    1_
$a Bansal, Aditya $u Ochsner Medical Center, New Orleans, Louisiana
700    1_
$a Takeda, Koji $u Columbia University College of Physicians and Surgeons and New York Presbyterian Hospital, New York
700    1_
$a Agarwal, Richa $u Duke University Medical Center, Durham, North Carolina
700    1_
$a Byku, Mirnela $u University of North Carolina at Chapel Hill, Chapel Hill
700    1_
$a Givertz, Michael M $u Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts
700    1_
$a Bitar, Abbas $u University of Michigan, Ann Arbor
700    1_
$a Hall, Shelley $u Baylor University Hospital, Dallas, Texas
700    1_
$a Zimpfer, Daniel $u Medical University of Vienna, Vienna, Austria
700    1_
$a Vega, J David $u Emory University Hospital, Atlanta, Georgia
700    1_
$a Kanwar, Manreet K $u Allegheny Health Network, Pittsburgh, Pennsylvania
700    1_
$a Saeed, Omar $u Montefiore Einstein Center for Heart and Vascular Care, New York, New York
700    1_
$a Goldstein, Daniel J $u Montefiore Einstein Center for Heart and Vascular Care, New York, New York
700    1_
$a Cogswell, Rebecca $u University of Minnesota Medical Center Fairview Minneapolis
700    1_
$a Sheikh, Farooq H $u Medstar Washington Hospital Center, Washington, DC
700    1_
$a Danter, Matthew $u Kansas University Medical Center, Kansas City
700    1_
$a Pya, Yuriy $u National Research Center for Cardiac Surgery, Kazakhstan
700    1_
$a Phancao, Anita $u Miami Transplant Institute-Jackson Memorial, Miami, Florida
700    1_
$a Henderson, John $u Abbott, Chicago, Illinois
700    1_
$a Crandall, Daniel L $u Abbott, Chicago, Illinois
700    1_
$a Sundareswaran, Kartik $u Abbott, Chicago, Illinois
700    1_
$a Soltesz, Edward $u The Cleveland Clinic Foundation, Cleveland, Ohio
700    1_
$a Estep, Jerry D $u The Cleveland Clinic Foundation, Cleveland, Ohio
710    2_
$a ARIES-HM3 Investigators
773    0_
$w MED00002973 $t JAMA (Chicago, Ill.) $x 1538-3598 $g Roč. 330, č. 22 (2023), s. 2171-2181
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37950897 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20240213093030 $b ABA008
999    __
$a ok $b bmc $g 2049118 $s 1209949
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 330 $c 22 $d 2171-2181 $e 2023Dec12 $i 1538-3598 $m JAMA (Chicago, Ill.) $n JAMA $x MED00002973
LZP    __
$a Pubmed-20240109

Najít záznam

Citační ukazatele

Možnosti archivace